<DOC>
	<DOCNO>NCT00771056</DOCNO>
	<brief_summary>Eligible CLL patient sign inform consent start hydroxychloroquine 400mg po daily one year . They monitor disease status well adverse reaction two week every 4 week . Ophthalmologic exam require baseline every 6 month sooner patient develops visual disturbance .</brief_summary>
	<brief_title>Hydroxychloroquine Untreated B-CLL Patients</brief_title>
	<detailed_description>This single-center , open-label , single arm Phase 2 study evaluate feasibility , efficacy treat CLL subject hydroxychloroquine . The study schema schedule event follow : Prior begin hydroxychloroquine : - Blood sample take . - Baseline test confirm diagnosis CLL define ( already obtain record ) - Physical exam perform - Either six month prior 4 week within start HCQ ophthalmologic exam document - Days 1-365 subject take hydroxychloroquine 400mg/day - At 2 week : CBC chemistry - Every 4 week : CBC , chemistry , history ( include inquiry presence absence visual symptom ) physical exam . - Starting 4 week : blood sample take laboratory companion study take office visit every 8 week . - At 6 month ( + - 30 day ) : subject follow ophthalmologic exam ) . This also do presence visual/ocular symptom . All subject must meet selection criterion registration study . All subject must peripheral blood sample submit . It estimate approximately 70 subject screen . The anticipated accrual period 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Flow cytometry confirm BCLL No prior chemotherapy immunotherapy Performance status 02 Age &gt; 18 year old If childbearing age , woman must willing use birth control length hydroxychloroquine use Must capacity consent study sign consent form Asymptomatic CLL require treatment time study entry Pregnancy Significant optic nerve pathology document opthalmologic exam Hypersensitivity 4aminoquinoline compound Patients take cardiac glycoside cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>untreated</keyword>
</DOC>